Oral Biolife Inc (OBL)

Oral Biolife has developed a ground breaking noninvasive treatment for Periodontal disease that regenerates bone tissue, reduces inflamation &disrupts Biofilms.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Bethlehem, PA, USA
  • Currency USD
  • Founded September 2022
  • Employees 5
  • Incorporation Type C-corp
  • Website oralbiolife.com

Company Summary

OralBiolife is an innovative biotech company utilizing piezo materials to develop a groundbreaking first to market product, AmberDent Gel for the treatment of periodontal disease. Oral Biolife has licensed the global exclusive rights from Temple University. Our product will launch in the companion animal market place with an identified animal health partner in 2024. The revenues will be used to accelerate the commericalizon for the human market.

Team

Advisors

  • Dr. Ronaldo Santana, Chair: Department of Periodontology and Oral Implantology; Director MSc Program & Research in Periodontology Temple University Kornberg Dental School
    Unconfirmed
    Dr. Tanya Kameneva, DVM University of Pennsylvania, Internal Medicine & Surgical Specialty, Animal Health, Doctor of Veterinary Medicine, Following was her Emergency and Internal Medicine Internship Training – Angel Memorial, Boston MA
    Unconfirmed
    Dr. Pascal Kunz, MD, DMD , Graduate of the University of Basel: Innovator in Dental MedTech, Digital Dentistry Diagnostics. Guided Surgery/Robic Surgery/Dental implants
    Unconfirmed
  • Lisa Stehno - Bittle, PhD;President and Founder at Likarda, Professor at University of Kansas. Hydro gel expert, developed the 3D cell culture platform at KU Med. Ctr where she focused on discovering and providing next-generation treatments for diabetes.
    Unconfirmed
    J. Todd Abrams

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free